No data are available in nursing mothers on the excretion into milk or safety of lofexidine in nursing mothers. A computer model predicted a maximum relative infant dose of about 3%, which should be acceptable. Although it is not contraindicated during breastfeeding, lofexidine should be used with caution until more data are available. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. A pharmacokinetic model was designed using in vitro-in vivo techniques that were then used to create a physiologically based pharmacokinetic model of lofexidine. A simulation of administering a dose of lofexidine to nursing mothers resulted in peak milk levels of about 4 mcg/L with a single 1.2 mg dose and 6 mcg/L with a single 2 mg dose assuming milk pH to be 6.8. Excretion was pH-sensitive, with levels dropping by over 90% at a pH of 7.[1] Using the peak level from a 2 mg maternal dose, the worst-case relative infant dose would be about 3%.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Dash SK, Rahman MA, Yi B, et al. Microfluidic blood-milk barrier and physiologically based pharmacokinetic model to predict lofexidine secretion into breast milk. J Pharm Sci 2025;114:103767. [PubMed: 40113090]
Substance Identification
Substance Name
Lofexidine
CAS Registry Number
31036-80-3
Drug Class
Breast Feeding
Lactation
Milk, Human
Adrenergic Alpha-2 Receptor Agonists,
Narcotic Antagonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.